Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield TX Drug List Coverage & Pri…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - TexasPolicy N/A

    2025 Drug List (Pharmacy Benefit) — Formulary and Utilization Management

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Texas policy alerts

    Know when Blue Cross Blue Shield - Texas releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists covered prescription and specialty drugs for Blue Cross and Blue Shield of Texas pharmacy benefit members, including tiers and utilization management (prior authorization, step therapy, quantity limits), and provider/member resources.

    Policy Summary
    PayerBlue Cross Blue Shield - Texas
    Policy2025 Drug List (Pharmacy Benefit) — Formulary and Utilization Management
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and submit supporting clinical documentation when a product is listed with 'PA' to avoid denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~120drug entries in this part (approx.)
    ~200distinct product lines in extract
    PAentries with Prior Authorization
    QLentries with Quantity Limits
    Accredospecialty pharmacy support

    Formulary Coverage Rules

    Covered when listed and plan conditions met

    Coverage of drugs on this list is governed by the drug list placement, plan-specific benefit design, and utilization management rules. Coverage applies when the drug appears on the list and any applicable plan conditions (PA, ST, QL) are met.

    General coverage conditions: Drug must be shown on the Drug List; member benefit must include coverage for that drug class; any required prior authorization, step therapy, quantity or dispensing limits must be satisfied.

    If a drug is not on the list it is not covered; some drugs may instead be covered under the medical benefit if provider-administered.

    Formulary coverage with product-specific requirements

    Coverage is product-specific; many antiviral and specialty drugs require authorization or are limited by quantity.

    Product-level coverage: Each listed product includes a Drug Tier and any Requirements/Limits (e.g., QL, PA, SP, AC). Coverage and access depend on meeting the listed requirements.

    Examples: BIKTARVY covered with QL 30/30; HARVONI requires PA and SP.

    Policy Summary
    PayerBlue Cross Blue Shield - Texas
    Policy2025 Drug List (Pharmacy Benefit) — Formulary and Utilization Management
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and submit supporting clinical documentation when a product is listed with 'PA' to avoid denial.
    SourceLink
    On This Page
    Formulary Coverage RulesDrug List and Billing IndicatorsPrescriber Responsibilities and Authorization ProcessPolicy BackgroundKey Terms and AbbreviationsInitial Dispensing and Therapy RequirementsStep Therapy ControlsQuantity Limits and Dispensing RestrictionsWhere Drugs Are Administered or Dispensed

    Formulary coverage flags and controls

    Coverage entries with utilization controls are listed; coverage stance is indicated by tier and requirement flags.

    Formulary Requirement Flags: Coverage determinations depend on listed flags: PA (prior authorization), QL (quantity limit), SP (specialty program/step), AC (administrative coverage flag for vaccines).

    No explicit clinical medical necessity criteria provided in this extract.

    Formulary coverage and utilization controls

    Drugs listed are part of the payer's 2025 drug formulary with associated utilization management controls; specific medical necessity criteria and exceptions are not provided in this excerpt.

    Formulary entry logic: Each drug entry includes drug name, strength, Drug Tier, and Requirements/Limits fields. Where Requirements/Limits include PA, coverage requires prior authorization; where QL is listed, dispensing is limited to the specified amount per time period; SP indicates specialty pharmacy dispensing is required.

    No patient-level clinical criteria provided in this section.

    Formulary coverage with utilization management

    Coverage and access are subject to the listed utilization management controls; drugs are included on the formulary with specified Drug Tier and Requirements/Limits.

    Formulary drug coverage conditions: Member coverage depends on (1) drug being on formulary tier and (2) meeting any listed Requirements/Limits (PA, QL, SP).

    Operational — follow payer PA/QL/SP processes

    Formulary coverage by product

    Coverage stance is product-specific as listed; most products are covered on the formulary with tier assignments and occasional PA/QL requirements.

    Formulary listing: Each listed drug is assigned a Drug Tier and may have Requirements/Limits noted; coverage follows the plan's formulary rules for that tier and any PA/QL flags.

    See individual product line for PA or QL flags.

    Covered with utilization controls

    Coverage subject to utilization controls as listed per product

    Formulary coverage conditions: Coverage and dispensing are governed by the product-specific designations: Drug Tier, PA (prior authorization), QL (quantity limit), and SP (specialty pharmacy). Prescribers must obtain PA when indicated and adhere to QL and specialty dispensing rules.

    applies per product entries in this section

    Coverage determination by product entry

    Formulary coverage with utilization management — products are assigned tiers and may have PA, QL, ST, or SP requirements.

    Formulary entry rule: Coverage and access are determined per listed product line by its Drug Tier and any attached Requirements/Limits (PA, QL, ST, SP).

    Specific clinical criteria are not provided in this excerpt; only utilization flags and limits are listed.

    Coverage applies only to medications that appear on the payer's Drug List. Drugs not shown on the Drug List are not covered. Coverage for listed products is determined by the member's benefit design and any utilization management controls shown on the product line (for example, PA for prior authorization, QL for quantity limits, and ST for step therapy). If a medication on the list has one of these requirements, the provider must satisfy that requirement to obtain coverage.

    The extract provided does not include explicit standalone exclusion statements beyond the general rule that drugs not on the Drug List are not covered. Product lines shown are formulary entries with tier and Requirements/Limits fields rather than a separate exclusions section.

    There is no explicit clinical exclusion language in these excerpts. The material in this segment records each product's Drug Tier and any associated utilization controls (e.g., QL, PA, AC) but does not state discrete clinical exclusion criteria.

    No explicit exclusion conditions are identified in this portion of the document. Entries list product names, tiers, and, where applicable, Requirements/Limits; they do not present separate exclusion rules in these chunks.

    This excerpt does not list explicit exclusions. The content shows formulary placements and utilization management controls (for example, PA, QL, SP) on product lines rather than standalone exclusion statements.

    No explicit clinical exclusions are stated in this extract. The section documents corticosteroid products and their Requirements/Limits where applicable but contains no separate exclusion language.

    This segment lists thyroid products and related agents with Drug Tier assignments and does not include explicit medical exclusion statements for the products shown.

    The document segment does not explicitly mark any products as excluded. Many product lines appear with empty or standard Requirements/Limits fields; absence of a Requirement/Limits entry in these chunks does not constitute an exclusion.

    No explicit exclusions are stated in this portion of the formulary. Entries describe respiratory products and associated quantity limits but do not provide standalone exclusion criteria.

    These chunks list specialty and gastrointestinal products with administrative controls (for example, PA, QL, SP) but do not provide explicit clinical coverage criteria or medical necessity exclusion statements; the controls are administrative rather than clinical exclusions.

    No explicit clinical exclusions are specified in this excerpt. The material presents product-level management flags (e.g., QL values for stimulant formulations) and tier assignments without separate statements that classify products as not medically necessary.

    Coverage may be limited to uses consistent with FDA-approved labeling and accepted evidence-based clinical practice guidelines. Uses outside labeled indications or recognized guidelines may be restricted and would require appropriate justification during authorization processes.

    This extract contains no explicit 'not medically necessary' determinations. The document indicates where utilization controls apply (PA, QL, ST) but does not label specific uses or products as 'not medically necessary' in these chunks.

    No 'not medically necessary' statements appear in this portion of the formulary extract. Entries show product-level requirements and quantity limits but do not make explicit NMN determinations.

    These excerpts do not include 'not medically necessary' statements. The listing format records drug tiering and utilization controls without NMN language.

    No explicit 'not medically necessary' determinations are provided in this segment. The content documents product entries and QL values where applicable but does not state NMN conclusions.

    This excerpt does not state 'not medically necessary' determinations. It lists thyroid and related agents with tier and Requirements/Limits information only.

    No explicit 'not medically necessary' determinations are presented here. The section focuses on formulary tiering and administrative controls rather than NMN rulings.

    No explicit 'not medically necessary' statements are present in this portion of the extract. Respiratory and inhaled products are listed with QL values and do not include NMN language.

    This excerpt does not contain 'Not Medically Necessary' statements. It records psychiatric and CNS product listings with tier and QL fields but no explicit NMN determinations.

    Drug List and Billing Indicators

    Notable product-level controlsNDC | mixed
    ARIKAYCE 590 mg/8.4mlamikacin sulfate liposome inhal susp 590 mg/8.4ml (base eq) — QL (235.2 mls/28 days), SP PA
    TOBRAMYCIN tobramycin nebu soln 300 mg/mltobramycin nebu soln 300 mg/ml — PA, QL (56 containers/56 days), SP
    TOBI PODHALER 28 mgtobramycin inhal cap 28 mg — QL (224 capsules/56 days), SP
    Formulary product entries (partial)mixed
    APRETUDE cabotegravir im extended release susp 600 mg/3mlDrug Tier = . Requirements/Limits = AC
    BIKTARVY bictegravir-emtricitabine-tenofovir af tab 30-120-15 mg, 50-200-25 mgDrug Tier = P. Requirements/Limits = QL (30 tablets/30 days)
    CIMDUO lamivudine-tenofovir disoproxil fumarate tab 300-300 mgDrug Tier = P. Requirements/Limits = QL (30 tablets/30 days)
    COMPLERA emtricitabine-rilpivirine-tenofovir df tab 200-25-300 mgDrug Tier = NP. Requirements/Limits = QL (30 tablets/30 days)
    DELSTRIGO doravirine-lamivudine-tenofovir df tab 100-300-300 mgDrug Tier = P. Requirements/Limits = QL (30 tablets/30 days)
    DESCOVY emtricitabine-tenofovir alafenamide fumarate tab 120-15 mgDrug Tier = P. Requirements/Limits = QL (30 tablets/30 days)
    DOVATO dolutegravir sodium-lamivudine tab 50-300 mgDrug Tier = P. Requirements/Limits = QL (30 tablets/30 days)
    EMTRIVA emtricitabine soln 10 mg/mlDrug Tier = NP. Requirements/Limits = QL (720 mls/30 days)
    EPCLUSA sofosbuvir-velpatasvir tab 200-50 mg, 400-100 mgDrug Tier = P. Requirements/Limits = .
    HARVONI ledipasvir-sofosbuvir tab 45-200 mg, 90-400 mgDrug Tier = P. Requirements/Limits = QL (30 tablets/30 days), SP PA
    1–10 of 18
    1/2
    Formulary entries (no billing codes)mixed
    No procedure/diagnosis/CPT/HCPCS/ICD-10 codes presentThis extract lists drug names, tiers, and requirement flags but does not contain billing or diagnosis codes.
    Drug entries (no CPT/HCPCS/ICD-10 codes provided)mixed
    N/ANo procedure, diagnosis, or billing codes provided in this part; entries are medication-level with strengths and utilization controls.
    Drug listing (no procedure/diagnosis codes included in excerpt)NDC | mixed
    No codes listed
    Drug listing (no billing codes provided)NDC
    NDC not listedNo NDC codes provided in this excerpt; only product names and strengths are listed.
    Formulary entries (no billing codes listed)mixed
    N/AThis document excerpt lists drugs and strengths; no explicit CPT/HCPCS/ICD-10 codes provided in this window.
    Drug list (no billing codes)NDC
    NDCs not listedThis excerpt lists product names and strengths but does not include NDC codes.
    Azithromycin tablet quantity limit
    Azithromycin tablet QLQL (60 tablets/180 days)
    Azithromycin suspensionsAzithromycin for susp 200 mg/5 mL listed (no QL specified)
    Clarithromycin ER QLClarithromycin ER 500 mg — QL (28 tablets/30 days)
    Fidaxomicin quantity limit
    Fidaxomicin productDIFICID fidaxomicin tab 200 mg and fidaxomicin for suspension 40 mg/mL listed on formulary
    Requirements/Limits notedFidaxomicin entries present but specific quantity limit period not specified in extract
    Drug TierDIFICID fidaxomicin tab 200 mg — Drug Tier = P
    Antiretroviral QLs
    BIKTARVYbictegravir-emtricitabine-tenofovir AF tab 30-120-15 mg, 50-200-25 mg — Requirements/Limits = QL (30 tablets/30 days)
    CIMDUOlamivudine-tenofovir disoproxil fumarate tab 300-300 mg — Requirements/Limits = QL (30 tablets/30 days)
    DOVATOdolutegravir-lamivudine tab 50-300 mg — Requirements/Limits = QL (30 tablets/30 days)
    ISENTRESSraltegravir potassium chew/tab/packet — Requirements/Limits = QL (varies by formulation; examples: QL 180 tablets/30 days for chew/tab)
    Common quantity limits
    Common tablet QLsExamples include QL (30 tablets/30 days), QL (60 tablets/30 days), QL (90 tablets/30 days)
    Common liquid QLsExamples include QL (720 mL/30 days), QL (100 mL/30 days) for selected formulations
    Pack/kit QLsExamples include QL (28 tablets/28 days) for pellet/packet packs
    Quantity limits examples
    Vancomycin capsulesVancomycin HCl capsules (Vancocin) — Requirements/Limits = QL (120 capsules/30 days)
    XIFAXAN 200 mgRifaximin 200 mg — Requirements/Limits = QL (9 tablets/30 days)
    XIFAXAN 550 mgRifaximin 550 mg — Requirements/Limits = QL (60 tablets/30 days)
    Quantity limits examples
    Prednisone (RAYOS)RAYOS prednisone delayed-release — Requirements/Limits = QL (30 tablets/30 days)
    MethyltestosteroneMETHITEST methyltestosterone oral tab 10 mg — Requirements/Limits = PA, QL (600 tablets/30 days)
    Contraceptive QLsExamples: QL (28 tablets/21 days) and ANNOVERA QL (1 ring/365 days)
    Quantity limits (examples)
    Oral suspension volume QLsExamples include QL (1920 mL/30 days) for selected products; KATERZIA amlodipine oral suspension — PA, QL (300 mL/30 days)
    QBRELIS metformin solutionQBRELIS listed with QL (2400 mL/30 days) in extract
    Epaned enalapril solutionEpaned listed with QL (1200 mL/30 days) example
    Quantity limits examples
    Inhaler and kit QLsExamples include QL (1 kit/21 days) and inhaler limits such as QL (2 inhalers/30 days) or QL (3 inhalers/30 days)
    ALYFTREKALYFTREK (vanzacaftor-tezacaftor-deutivacaftor) — Requirements/Limits = PA, QL (56 tablets/28 days) or QL (84 tablets/28 days) depending on formulation, SP
    VENTOLIN HFAVENTOLIN HFA (albuterol inhaler) — Requirements/Limits = QL (2 inhalers/30 days)
    Common Quantity Limits
    Common QL setCommon quantity limits used across the formulary: QL (30 tablets/30 days), QL (60 tablets/30 days), QL (90 tablets/30 days)
    Large-volume oral solutionsExamples include aripiprazole oral solution — QL (900 mL/30 days)
    Psychotropic QLsQuetiapine, olanzapine and similar agents listed with QL examples (e.g., QL 30 or 60 tablets/30 days)

    Prescriber Responsibilities and Authorization Process

    Prior Authorization

    Prior authorization required when 'PA' is noted

    Obtain prior authorization (PA) when a product line lists 'PA' in the Requirements/Limits column; PA must be approved before the medication will be covered under the plan.

    • PA is indicated next to medications where preapproval is required (Special Requirements = 'PA').
    • Failure to obtain an approved PA may result in denial or noncoverage.
    Prior Authorization

    PA required for select agents (e.g., inhaled aminoglycosides)

    Follow the formulary entries for select agents that carry PA or SP flags (examples include inhaled aminoglycosides and tobramycin products); obtain PA and coordinate specialty pharmacy dispensing where indicated.

    • Tobramycin nebu soln 300 mg/ml: Requirements/Limits = PA, QL (56 containers/56 days), SP.
    • TOBI PODHALER 28 mg: Requirements/Limits = QL (224 capsules/56 days), SP.
    Prior Authorization

    Prior authorization for selected antivirals

    Request prior authorization for high-cost antiviral agents when indicated; many hepatitis C and antiretroviral products list PA and/or specialty pharmacy (SP) requirements.

    • HARVONI (ledipasvir-sofosbuvir): Requirements/Limits = PA, QL (30 tablets/30 days), SP.
    • SOVALDI (sofosbuvir): Requirements/Limits = PA, QL (30 tablets/30 days), SP; MAVYRET: PA, QL, SP as listed.
    Prior Authorization

    PA requirement for oncology & specialty drugs

    Many oncology and specialty agents require prior authorization; obtain PA before dispensing to avoid denial because numerous antineoplastics list PA in Requirements/Limits.

    • Examples: ALECENSA, ALUNBRIG, BRAFTOVI and others show 'PA' (often with QL and SP).
    • PA is required for coverage of these specialty oncology products.
    Prior Authorization

    Submit PA when 'Requirements/Limits = PA' is listed

    When a drug's Requirements/Limits field equals 'PA', prescribers must submit a prior authorization request with supporting clinical information demonstrating medical necessity.

    • PA entries require documentation of diagnosis, dosing and rationale.
    • Use the phone number on the member ID card for exception or expedited requests as needed.
    Prior Authorization

    PA required for multiple listed products

    Obtain prior authorization for many listed products annotated with 'PA' (examples across multiple sections); do not dispense before PA approval when PA is indicated.

    • Testosterone products and several other listed items carry 'PA' flags — secure PA to prevent claim denial.
    • Check each product line for a PA annotation prior to dispensing.
    Prior Authorization

    PA required for certain testosterone products

    Prior authorization is required for specified testosterone formulations shown with 'PA' in Requirements/Limits; follow PA processes and document quantity limits where noted.

    • Example: METHITEST methyltestosterone — Requirements/Limits = PA, QL (600 tablets/30 days).
    • Testosterone TD gels and injectables list PA and QL values — obtain PA before dispensing.
    Prior Authorization

    PA required for certain metformin ER formulations

    Prior authorization applies to specified formulations of metformin ER/osmotic forms when annotated 'PA' or 'PA, QL'; providers must obtain PA and adhere to the stated QL.

    • metformin HCl ER osmotic 1000 mg: Requirements/Limits = PA, QL (60 tablets/30 days).
    • Ensure prescriptions align with listed QLs to avoid denial.
    Prior Authorization

    Follow PA and specialty pharmacy (SP) procedures when flagged

    Products marked with 'PA' and/or 'SP' require submission of prior authorization and, when applicable, coordination with specialty pharmacy channels before coverage is approved.

    • Examples: ACTHAR, GENOTROPIN and SOMAVERT list PA and SP in Requirements/Limits.
    • Follow payer PA/SP procedures for submission and dispensing.
    Prior Authorization

    PA required for selected extended‑release beta blockers

    Certain extended‑release beta‑blocker products (e.g., INDERAL XL, INNOPRAN XL) are listed with 'PA' — obtain prior authorization for these formulations prior to coverage.

    • INDERAL XL and INNOPRAN XL have Requirements/Limits = PA.
    • Secure PA to prevent claim denial for these ER beta‑blockers.
    Prior Authorization

    PA required for selected specialty/biologic agents

    Obtain prior authorization for respiratory and biologic specialty agents listed with 'PA' and coordinate specialty pharmacy dispensing (SP) when required for coverage.

    • Examples: FASENRA PEN — Requirements/Limits = PA, QL (pen/28 days), SP; XOLAIR — Requirements/Limits = PA, SP.
    • Failure to obtain PA or use the specialty pharmacy may lead to denial.
    Prior Authorization

    PA required for listed specialty agents (CF modulators, others)

    Numerous specialty and high‑cost agents (e.g., ALYFTREK, KALYDECO, TRIKAFTA, ENTYVIO PEN, OMVOH) list 'PA' in Requirements/Limits — obtain PA before dispensing.

    • ALYFTREK: Requirements/Limits = PA, QL, SP as shown.
    • TRIKAFTA and other CF modulators list PA + QL + SP — secure PA and follow QL.
    Prior Authorization

    Obtain PA for numerous listed agents

    Many agents throughout the list require prior authorization; providers must obtain PA before coverage is approved for these products to avoid denied claims.

    • Examples: LIVDELZI, LIVMARLI, OMVOH, SKYRIZI and VOWST list PA in Requirements/Limits.
    • Submit PA with supporting clinical documentation and follow specialty pharmacy instructions when present.
    Prior Authorization

    PA required for select specialty drugs (examples)

    Certain specialty medications (e.g., IMCIVREE, tasimelteon) require prior authorization when listed; follow PA processes and respect any quantity limits (QL) noted.

    • IMCIVREE: Requirements/Limits = PA, QL (10 vials/30 days), SP.
    • Tasimelteon (Hetlioz) and select antipsychotic entries carry PA when indicated.
    Step Therapy

    Step therapy (ST) applies where 'ST' is listed

    Step therapy may be required for some medications and is indicated by 'ST' in the Special Requirements column; follow plan step‑therapy rules where 'ST' is shown.

    • ST appears next to certain antidepressants and CNS agents (e.g., AUVELITY, FETZIMA, FLUOXETINE DR entries).
    • Providers must document failure or intolerance of required prior steps if requesting coverage for ST‑listed agents.
    Note
    Documentation Required

    Products with additional clinical criteria (AC flag)

    Products flagged 'AC' indicate additional clinical or administrative criteria; prescribers must meet those additional conditions (e.g., APRETUDE shows 'AC').

    • APRETUDE cabotegravir IM extended release: Requirements/Limits = AC.
    • AC flags may represent additional documentation or eligibility criteria required for coverage.
    Note

    Specialty pharmacy / step program flags (SP)

    Entries marked 'SP' indicate specialty program or specialty pharmacy handling; where 'SP' appears providers must follow specialty program requirements and dispensing channels.

    • Many oncology, biologic and cystic fibrosis agents are designated 'SP' and require specialty pharmacy dispensing.
    • SP entries commonly appear alongside PA and QL.
    Note
    Note

    Utilization management indicators require provider action

    The formulary uses utilization management indicators (PA, QL, SP, AC) to control access; when these appear providers must follow the listed controls to avoid denials.

    • PA = prior authorization; QL = quantity limit; SP = specialty pharmacy; AC = additional criteria/administrative flag.
    • Noncompliance with these flags may lead to denied or limited coverage.
    Documentation Required

    Contraceptive entries with AC, PA, and QL flags

    Some contraceptive products include 'AC' and may also carry PA and QL annotations; providers must follow those administrative and quantity requirements when prescribing.

    • Examples: drospirenone-ethinyl estradiol (Yaz) — Requirements/Limits = AC, QL (28 tablets/21 days); some contraceptives list AC, PA, QL.
    • Claims exceeding QL or lacking required administrative criteria risk denial.
    Note

    No explicit step‑therapy sequence provided for many products

    Where step therapy is not specified in the formulary excerpt, providers must still follow any PA, QL or SP controls shown for the product; explicit multi‑step sequences are not provided here.

    • Many entries list PA/QL/SP but do not include explicit ST sequences in this excerpt.
    • When ST is absent, ensure PA/QL/SP requirements are met for coverage.
    Note

    SP flags indicate specialty program/step requirements

    Some product lines show SP flags which imply step or specialty program controls; where SP is present follow payer step edit and specialty program requirements.

    • Products marked 'SP' (e.g., GENOTROPIN, CRENESSITY) require adherence to specialty program rules and may also require PA/QL.
    • Providers should use the payer's step‑edit processes when requesting SP agents.
    Note

    Step therapy not specified for most entries in this excerpt

    This extract does not list step‑therapy rules for many products; where ST appears it is limited to selected agents (noted separately). For other products, follow PA/QL/SP controls documented on the product line.

    • No explicit ST algorithms are included in these chunks; use product Requirements/Limits to determine provider actions.
    • When in doubt, submit PA with full clinical rationale.
    Note

    When ST not specified, follow PA/QL/SP controls

    Where step therapy is not described, providers must still obtain prior authorization and document adherence to QL and SP requirements shown on product lines to avoid denials.

    • Many products rely on PA/QL/SP flags instead of step therapy sequences in this excerpt.
    • Follow the plan's PA submission requirements and include supporting clinical documentation.
    Note

    Step therapy not detailed in this section

    This segment does not present explicit step therapy sequences; providers must rely on the Requirements/Limits (PA, QL, SP) shown per product when requesting coverage.

    • For products with 'ST' elsewhere in the list, follow the payer's step edit requirements.
    • Document prior steps if requesting overrides for ST‑listed agents.
    Step Therapy

    Step therapy applies to selected antidepressants/CNS agents

    Selected antidepressants and related CNS agents are marked 'ST' — providers must follow step therapy protocols when requesting coverage for these medicines.

    • AUVELITY, FETZIMA, FLUOXETINE DR and some paroxetine and sertraline entries are designated ST.
    • If requesting an ST agent, document failure or intolerance of required prior therapies.
    Step Therapy

    ST indicated for select products (paroxetine, clozapine ODT)

    Multiple products are marked 'ST' in the list (examples include paroxetine oral suspension and clozapine ODT); providers must document previous therapy trials per the payer's step program when submitting requests.

    • PAROXETINE oral suspension and CLOZAPINE ODT entries include ST alongside QL.
    • Include prior treatment history when submitting PA or exception requests for ST agents.
    Documentation Required

    Prescriber submission route for Drug List exceptions / expedited review

    For Drug List exceptions or expedited reviews, the prescriber or authorized representative must submit the request via the phone number on the member's ID card; the payer will notify the prescriber and member of the decision within two business days (or within 72 hours for expedited requests).

    • Use the phone number on the member ID card to request an exception.
    • Standard decisions: within two business days; expedited: within 72 hours.
    Prior Authorization

    Follow PA/QL procedures for flagged products

    Follow the plan's PA/QL procedures for products with QL, PA or SP flags (examples include azithromycin QL and ARIKAYCE PA/QL/SP); submit PA requests and document QL adherence on claims.

    • Azithromycin tablet: QL (60 tablets/180 days).
    • ARIKAYCE: Requirements/Limits include QL and SP/PA — follow PA/QL/SP submission steps.
    Documentation Required

    Document QL and PA indicators on PA requests and claims

    When a product lists QL and PA/SP flags, ensure the quantity limits and authorization indicators are documented on the PA request and on the pharmacy claim to support coverage.

    • Examples: BIKTARVY QL (30 tablets/30 days); HARVONI QL (30 tablets/30 days) with PA and SP.
    • Include quantity and timeframe details from the Requirements/Limits field in submissions.
    Prior Authorization

    Products marked 'PA' require prior authorization

    Products labeled 'PA' in the formulary require prior authorization per the listing; providers must obtain PA before dispensing to ensure coverage.

    • Many antineoplastic and specialty agents explicitly show 'PA' — obtain authorization prior to dispensing.
    • Claims submitted without required PA may be denied.
    Documentation Required

    Submit PA/QL/SP documentation when indicated

    When PA, QL, or SP apply, prescribers must submit required prior authorization documentation as specified; include clinical justification for the request.

    • PA/QL/SP documentation should include diagnosis, prior therapy history, dosing and quantity justification.
    • Specialty agents typically require submission to specialty pharmacy channels and PA processes.
    Documentation Required

    Provide supporting clinical documentation with PA requests

    Provide clinical documentation to support PA requests for products with 'PA' noted (include diagnosis, dosing, prior therapy and quantity justification as applicable).

    • Include relevant clinical records and prior treatment history when requesting PA.
    • Expedited requests must include supporting information to justify the urgent need.
    Billing Rule

    Document Requirements/Limits on the claim per product listing

    Follow the product-level Requirements/Limits fields when submitting claims — include drug tier, PA, QL and SP details from the formulary entry on the claim to facilitate processing.

    • Entries list Drug Tier and Requirements/Limits (e.g., PA, QL amounts and timeframes) that must be respected when submitting pharmacy claims.
    • Claims lacking required PA or exceeding QL may be denied or partially paid.
    Documentation Required

    Ensure prescriptions conform to specified QLs or obtain PA

    When a product lists a specific quantity limit (QL), ensure prescriptions and PA requests align with the stated QL to avoid denial or out‑of‑pocket responsibility for excess quantities.

    • Examples: metformin ER osmotic forms list PA and QL values; azithromycin QL (60 tablets/180 days).
    • If dosing requires exceeding the QL, submit PA with justification before dispensing.
    Documentation Required

    Attach supporting documentation for PA/QL (specialty products)

    Provide supporting clinical documentation for PA/QL requests where products are designated 'PA' or 'SP', and include quantity limits when specified (e.g., GALAFOLD, CRENESSITY).

    • GALAFOLD: Requirements/Limits = PA, QL (14 capsules/28 days), SP — include clinical rationale in PA submission.
    • CRENESSITY: Requirements/Limits = PA, QL (60 capsules/30 days), SP — document diagnosis and dosing.
    Documentation Required

    Document QL volumes for oral suspensions/solutions

    Quantity limits for oral suspensions and solutions are specified and must be documented (examples include KATERZIA and other suspension products); include volume and timeframe in requests.

    • KATERZIA: Requirements/Limits = PA, QL (300 ml/30 days).
    • Some entries list large-volume QLs (e.g., 1920 ml/30 days) — document clinical need if requesting override.
    Billing Rule

    Respect product QLs and include on PA/claim submissions

    When a product has a defined QL (e.g., ALYFTREK, IMCIVREE), ensure dispensing is within the specified quantity or obtain an approved override; include QL details in PA submissions.

    • ALYFTREK: QL examples = 84 tablets/28 days or 56 tablets/28 days depending on formulation.
    • IMCIVREE: Requirements/Limits = PA, QL (10 vials/30 days).
    Documentation Required

    Supply required PA documentation on submission

    Providers must supply the documentation required by prior authorization processes when submitting for drugs noted 'PA' (diagnosis, prior treatment, dosing and quantity justification).

    • Use the payer's PA forms/process and include required clinical information.
    • Expedited reviews are available for urgent clinical situations (decision within 72 hours).
    Documentation Required

    Submit PA and supporting clinical documentation when PA/QL/ST/SP indicated

    When products list 'PA', 'QL', 'ST' or 'SP', submit prior authorization and supporting clinical documentation and prescribe within the listed quantity limits and specialty pharmacy channels as specified.

    • OMVOH: Requirements/Limits = PA, QL (2 pens/28 days) or QL (2 syringes/28 days), SP — include clinical documentation with PA.
    • SKYRIZI: Requirements/Limits = PA, QL (1 cartridge/56 days), SP.
    Prior Authorization

    Obtain PA and observe QL for PA‑listed products

    Providers must submit prior authorization when a product entry includes 'PA'; quantity limits must be respected per product QL entries (e.g., IMCIVREE QL 10 vials/30 days).

    • IMCIVREE: Requirements/Limits = PA, QL (10 vials/30 days), SP.
    • Follow the documented QL and include justification if requesting additional quantity.
    Denial Risk

    Noncoverage risk for drugs not on the Drug List

    Drugs not shown on the formulary are not covered; prescribing a non‑listed drug without an approved Drug List exception or PA may result in noncoverage.

    • If a drug is not on the Drug List, request a Drug List exception via the phone number on the member ID card.
    • BCBSTX will notify prescriber/member of the decision within two business days (or 72 hours for expedited reviews).
    Denial Risk

    PA/QL denial risk for inhaled aminoglycosides

    Prescriptions for inhaled or nebulized aminoglycosides and tobramycin products show PA/SP/QL designations; failure to obtain PA or exceeding QL may trigger denial.

    • Tobramycin nebu soln 300 mg/ml: Requirements/Limits = PA, QL (56 containers/56 days), SP.
    • ARIKAYCE (amikacin liposome inhal): QL (235.2 mls/28 days), SP/PA as listed.
    Denial Risk

    PA/SP/AC flags — coverage denial risk if unmet

    Entries marked with PA, SP, or AC indicate prior authorization, specialty pharmacy, or additional clinical requirements which, if not met, can trigger denial of coverage.

    • HARVONI and SOVALDI list PA and SP along with QL — missing PA or wrong dispensing channel risks denial.
    • AC flags (e.g., APRETUDE) indicate additional clinical criteria that must be satisfied.
    Denial Risk

    PA triggers for antineoplastics — denial risk if not obtained

    Prior authorization is required for many antineoplastic and specialty products; failure to obtain PA where listed may result in coverage denial or restriction.

    • Examples: abiraterone acetate (Zytiga) — Requirements/Limits = PA, QL (60 tablets/30 days), SP.
    • BOSULIF and BRAFTOVI entries show PA with QL and SP — obtain PA to secure coverage.
    Denial Risk

    Claims risk if PA not obtained where listed

    Coverage may be denied or restricted if prior authorization is not obtained for a drug when the formulary lists 'PA' next to the product.

    • Many products in the listing require PA as indicated — secure PA before dispensing.
    • Claims submitted without required PA are at risk for denial.
    Denial Risk

    PA triggers for hormone and contraceptive formulations

    Prior authorization is required for multiple testosterone and estrogen formulations shown with 'PA'; dispensing without PA risks claim denial.

    • Examples: multiple testosterone TD gels and injectables list PA and QL (e.g., testosterone TD gel — PA, QL (30 packets/30 days)).
    • Some contraceptive products list AC, PA and QL — follow administrative requirements.
    Denial Risk

    Quantity limit triggers for contraceptives — denial risk if exceeded

    Quantity limits (QL) on contraceptives and related products (e.g., 28 tablets/21 days, 2 tablets/365 days) are enforced; claims exceeding QL or lacking documentation may be denied.

    • drospirenone‑ethinyl estradiol (Yaz): Requirements/Limits = AC, QL (28 tablets/21 days).
    • ELLA: Requirements/Limits = AC, QL (2 tablets/365 days).
    Denial Risk

    Prior authorization risk for 'PA' / 'PA, QL' entries

    Products listed with 'PA' or 'PA, QL' indicate prior authorization may be required and claims may be denied without PA; obtain PA and document QL adherence.

    • Metformin ER osmotic forms and other listed products show 'PA, QL' — secure PA before dispensing.
    • Claims missing PA documentation are subject to denial.
    Denial Risk

    Noncompliance with PA/QL/SP may cause denial

    Coverage may be denied or limited if Prior Authorization (PA), Quantity Limits (QL), or Step Program (SP) requirements listed for specific products are not met; ensure compliance with all listed controls.

    • Noncompliance with PA/QL/SP on specialty products like IMCIVREE or GENOTROPIN can result in denial or limited coverage.
    • Submit full supporting documentation when seeking exceptions or overrides.
    Denial Risk

    PA/QL trigger — denial risk if requirements unmet

    Products noted with 'PA' or 'QL' may trigger a prior authorization or quantity‑limit denial if the listed requirements are not met; confirm PA approval and QL compliance prior to dispensing.

    • Example: KATERZIA: Requirements/Limits = PA, QL (300 ml/30 days).
    • VENTOLIN HFA: QL (2 inhalers/30 days) — exceeding QL without approval risks denial.
    Denial Risk

    PA and specialty pharmacy requirements create denial risk if unmet

    Drugs listed with 'PA' and 'SP' designations (e.g., FASENRA PEN, NUCALA, XOLAIR) require prior authorization and may be dispensed via specialty pharmacy; failure to obtain PA or use SP may trigger denial or noncoverage.

    • FASENRA PEN: Requirements/Limits = PA, QL (pen/28 days), SP.
    • XOLAIR: Requirements/Limits = PA, SP — obtain PA and route dispensing through specialty pharmacy.
    Prior Authorization

    Specialty pharmacy requirement — PA + SP must be followed

    Entries that require specialty pharmacy (SP) must be dispensed through the specialty channel when indicated; failure to use SP or obtain PA may result in denial.

    • ALYFTREK: Requirements/Limits = PA, QL, SP — specialty dispensing is required.
    • Many biologic and infusion products list SP alongside PA and QL.
    Denial Risk

    Quantity limit exceedance risks denial without override

    Requests that exceed specified quantity limits (QL) without an approved override are at risk for denial; submit PA with justification if a larger quantity is clinically necessary.

    • PAXLOVID QL examples: QL (20 tablets/90 days) or QL (30 tablets/90 days) depending on pack.
    • Requests exceeding tablet/packet QLs or annual limits require documented override approval.
    Documentation Required

    Authorization documentation required for PA/QL/ST/SP triggers

    When a drug line requires Prior Authorization (PA), Quantity Limits (QL), Step Therapy (ST) or Specialty Pharmacy (SP), requests must be accompanied by the required authorization documentation to avoid denial.

    • OMVOH and SKYRIZI entries include PA, QL and SP — include the PA approval and QL adherence on claims.
    • Missing documentation for any of these controls may result in denial of coverage.
    Note

    PA/QL/ST program triggers — follow listed program controls

    Medications listed with 'PA', 'ST' or 'QL' require adherence to the stated prior authorization, step therapy or quantity limits; follow the product Requirements/Limits and include supporting documentation when seeking exceptions.

    • IMCIVREE: Requirements/Limits = PA, QL (10 vials/30 days), SP — follow PA/QL/SP rules.
    • For ST‑marked agents, document prior trials and failures as part of the request.
    Note

    Policy Background

    Decisions about individual patient therapy remain between the patient and the prescribing clinician. Specialty drugs treat complex conditions and may be self-administered or require administration by a health care professional. The payer selects drugs for the list based on FDA regulation and multidisciplinary review; utilization controls on the list (for example, PA, QL, ST) reflect coverage management rather than direct clinical guidance.

    Key Terms and Abbreviations

    inv-106: Specialty drugs — definition and examples
    DefinitionSpecialty drugs are used to treat complex conditions (e.g., hepatitis, hemophilia, multiple sclerosis, rheumatoid arthritis) and may be oral, topical, or injectable; some require administration by a health care professional
    Coverage noteMedications administered by a health care professional may be covered under the medical benefit rather than the pharmacy benefit
    Where to find listFor a current list of specialty medications, visit MyPrime.com or bcbstx.com
    inv-107: Generic equivalent vs generic alternative
    Generic equivalentA generic equivalent uses the same active ingredient(s) at the same dosage as the reference (brand) drug
    Generic alternativeA generic alternative treats the same condition but may contain different active ingredient(s)
    ImplicationBrand may be moved to a higher tier or removed after a generic equivalent becomes available; members may be responsible for cost difference if requesting brand over generic
    inv-108: Drug Tier — plan-assigned tier designation for each medication (e.g., P, NP, NP).
    What it meansDrug Tier is the plan‑assigned category indicating formulary placement and member cost‑sharing (examples include P, NP, P+)
    ExamplesEntries across the list show tiers such as P (Preferred), NP (Non‑Preferred), and P+ in some product lines
    ActionCheck the product line for the specific Tier to determine member cost share and coverage implications
    inv-109: QL / PA / SP abbreviations
    QLQuantity Limit — maximum allowable quantity per specified time period, noted as 'QL' next to product entries
    PAPrior Authorization — coverage requires preapproval; indicated by 'PA' in Requirements/Limits
    SPSpecialty Pharmacy — product must be dispensed through specialty pharmacy channels; indicated by 'SP'
    inv-110: PA — Prior Authorization definition
    DefinitionPrior Authorization (PA) — coverage for the listed product requires preapproval by the payer and is indicated by 'PA' in the Requirements/Limits column
    When requiredMany specialty, oncology, antiviral, and certain high‑cost agents list PA (examples include HARVONI, IMCIVREE, various oncology drugs)
    Provider actionObtain PA prior to dispensing to avoid denial; supply supporting clinical documentation per PA process
    inv-111: SP — Specialty Pharmacy definition
    DefinitionSpecialty Pharmacy (SP) — medication designated to be dispensed via specialty pharmacy channels and often subject to additional management
    ExamplesProducts such as XOLAIR, OMVOH, many biologics and cystic fibrosis modulators are marked SP
    ImplicationSP items may require use of the payer's designated specialty pharmacy and PA before coverage
    inv-112: QL — Quantity Limit definition
    DefinitionQuantity Limit (QL) — maximum allowed quantity per specified timeframe (e.g., 30 tablets/30 days), shown on product lines as 'QL'
    FormatUsually formatted as QL (count/unit / time period) — e.g., QL (30 tablets/30 days), QL (120 capsules/30 days)
    ConsequenceDispensing beyond QL may be denied or the member may be responsible for costs beyond allowed quantity
    inv-113: AC — Additional Criteria flag definition
    DefinitionAC — Additional Criteria or clinical/administrative review required (flag shown next to certain products)
    UsageUsed where extra clinical documentation or specific conditions are required for coverage (e.g., APRETUDE marked AC)
    Follow-upProviders should follow payer guidance when AC is indicated to support coverage
    inv-114: PALFORZIA levels — dose level definitions
    PALFORZIA levelsCommercially packaged dose levels for peanut allergen powder listed Level 0 through Level 11 with associated milligram doses
    Program flagsPALFORZIA entries carry SP or other restrictions in the list (maintenance and titration packets noted)
    IndicationUsed for oral immunotherapy for peanut allergy; follow product and payer requirements
    inv-115: QL examples
    Example QLsQL (120 capsules/30 days) — vancomycin; QL (60 tablets/30 days) — select oncology/antiviral products
    VarietyExamples span tablets, capsules, mL volumes, inhalers, kits and yearly supplies
    RecommendationAlways confirm the exact QL on the product line before authorizing or dispensing
    inv-116: PA examples
    PA examplesHARVONI (ledipasvir-sofosbuvir) — PA, SP; many oncology and specialty agents list PA
    When PA appliesPA appears alongside QL and SP for drugs such as AUGTYRO, ALYFTREK, IMCIVREE
    Provider actionSubmit required clinical documentation per PA process to obtain coverage approval
    inv-117: Utilization management abbreviations
    Abbreviations listPA = Prior Authorization; QL = Quantity Limit; SP = Specialty Pharmacy; ST = Step Therapy; AC = Additional Criteria
    PurposeThese flags indicate utilization management controls applied to specific product lines
    Where shownFlags appear in the Requirements/Limits column beside each product entry
    inv-118: PA (restate)
    PA (restate)Prior Authorization — PA shown on product line indicates preapproval required for coverage
    EffectClaims may be denied if PA is not obtained where listed
    ExamplesSeveral antivirals and oncology drugs list PA (e.g., HARVONI, AUGTYRO)
    inv-119: QL (restate)
    QL (restate)Quantity Limit — a cap on units dispensed in a time period (e.g., 30 tablets/30 days); listed as QL on product lines
    ImpactDispensing beyond QL without approved override may result in denial or member financial liability
    ExamplesVANCOMYCIN QL (120 capsules/30 days); XIFAXAN 200 mg QL (9 tablets/30 days)
    inv-120: SP (restate)
    SP (restate)Specialty Pharmacy — product designated SP must be dispensed via specialty pharmacy channels
    ExamplesXOLAIR, OMVOH, many biologics and cystic fibrosis modulators are SP-designated
    Provider actionFollow payer specialty pharmacy routing and PA processes for SP items
    inv-121: AC (restate)
    AC (restate)AC indicates Additional Criteria/clinical review required before coverage
    ExampleAPRETUDE shown with AC in the list
    ActionProvide supporting clinical documentation when AC is flagged
    inv-122: QL (format examples)
    QL format examplesQL (30 tablets/30 days); QL (120 capsules/30 days); QL (720 mL/30 days)
    Alternate formatsQL may be expressed per 28 days, 56 days, 180 days, or per year depending on product
    InterpretationExact period should be read from the product line (e.g., QL (60 tablets/180 days) for azithromycin)
    inv-123: PA (restate)
    PA (restate)Prior Authorization — re-emphasized: required for many specialty and antiviral products (PA shown on product line)
    ExamplesHARVONI, SOVALDI, many oncology agents list PA
    Provider stepObtain PA prior to dispensing to avoid denial
    inv-124: QL (restate)
    QL (restate)Quantity limits presented per product — e.g., QL (120 capsules/30 days), QL (60 tablets/30 days)
    Verify per productConfirm QL timeframe and units on the product line before filling
    DocumentationProvide quantity justification with PA requests if requesting above QL
    inv-124: Drug Tier abbreviations (P, NP) explained
    Drug Tier abbreviationsP = Preferred; NP = Non‑Preferred (tier codes indicate formulary placement)
    UsageTier affects member cost‑sharing and may interact with utilization controls
    Check product lineVerify tier assignment listed for each medication to determine coverage/cost implications
    inv-125: Drug Tier — plan-assigned category
    DefinitionDrug Tier — plan‑assigned category indicating formulary placement and member cost‑sharing (e.g., P, NP, P+)
    ImplicationTier combined with Requirements/Limits determines coverage and member responsibility
    ActionReview the product line for both tier and utilization flags when assessing coverage
    inv-126: Requirements/Limits — definition
    DefinitionRequirements/Limits — utilization management flags applied to the product such as PA, QL, SP, ST, AC
    Displayed on listShown in the Requirements/Limits column beside each product entry
    Provider implicationWhen Requirements/Limits are present, providers must follow the listed processes (PA requests, adhere to QL, use SP) to secure coverage
    inv-127: Drug Tier flags
    Drug Tier flagsTier codes such as P or NP appear next to product names to denote formulary placement
    ExamplesMany specialty biologics and respiratory agents are shown with P or NP tier assignments
    UseTier influences member cost share and may interact with PA/QL requirements
    inv-128: PA (restate)
    PA (restate)Prior Authorization — coverage requires preapproval when 'PA' is listed; obtain PA before dispensing
    ExamplesNoted across antivirals, oncology, and specialty products (HARVONI, AUGTYRO, many others)
    RiskFailure to obtain PA may result in claim denial or member financial responsibility
    inv-129: QL (restate)
    QL (restate)Quantity Limit — maximum dispense per timeframe; shown as QL (count/period) on product lines
    ExamplesVancomycin QL (120 capsules/30 days); XIFAXAN 200 mg QL (9 tablets/30 days)
    ActionRespect QL when filling or request PA/override with documentation for larger quantities
    inv-130: SP (restate)
    SP (restate)Specialty Pharmacy — SP flag indicates the product is to be dispensed via specialty pharmacy channels
    ExamplesMany biologics and specialty oral agents carry SP designation (e.g., XOLAIR, KALYDECO)
    Provider actionUse designated specialty pharmacy and follow PA/SP processes for coverage
    inv-131: PA (restate)
    PA (restate)PA indicates preapproval required; listed on many high‑cost and specialty agents
    ImplicationSubmit clinical documentation via PA process to support medical necessity
    ExamplesAppears with QL and SP on agents like HARVONI and select oncology drugs
    inv-132: QL (restate)
    QL (restate)Quantity Limit — maximum units allowed per specified interval; verify the exact units/timeframe on the product line
    ExamplesCommonly QL (30 tablets/30 days), QL (56 capsules/28 days), QL (120 capsules/30 days)
    Provider actionAdhere to QL or request an override with PA and supporting documentation
    inv-133: SP (restate)
    SP (restate)Specialty Pharmacy designation — product managed through specialty channel when 'SP' listed
    ExamplesXOLAIR and many biologics require SP dispensing
    ActionCoordinate with the payer's specialty pharmacy and obtain PA as required
    inv-134: PA (restate)
    PA (restate)Prior Authorization — obtain prior approval when 'PA' is present on product line
    ExamplesCommon across antivirals, oncology, and specialty therapies
    ConsequencesClaims may be denied without PA; follow payer PA timelines and documentation requirements
    inv-135: QL (restate)
    QL (restate)Quantity Limit — maximum units per interval indicated as QL; check per‑product entry for exact amount/timeframe
    ExamplesQL (1 cartridge/56 days), QL (2 syringes/28 days), QL (12 capsules/12 months)
    Provider actionDocument and justify quantities when requesting overrides or PA for amounts above QL
    inv-136: AC (administrative coverage) — contraceptive example
    AC — administrative coverage exampleAC appears as an access/control flag for contraceptive products (e.g., some oral contraceptives noted with AC, QL)
    ImplicationAdministrative coverage flags may indicate restricted access pathways or special dispensing rules
    Provider actionFollow payer administrative instructions for products flagged AC
    inv-137: PA (restate)
    PA (restate)Prior Authorization — when shown, obtain preapproval before dispensing
    ExamplesAppears with many specialty and oncology agents
    RiskCoverage may be denied without PA
    inv-138: QL (restate)
    QL (restate)Quantity Limit — specified per product (count/period), adherence required for coverage
    ExamplesQL (28 tablets/21 days) for many contraceptives; QL (30 tablets/30 days) for many agents
    ActionVerify QL before dispensing to avoid denial or member liability
    inv-139: SP (restate)
    SP (restate)Specialty Pharmacy — SP indicates specialty dispensing and management for the product
    ExamplesMany biologics, cystic fibrosis modulators, and selected inhaled therapies are SP-designated
    Provider actionCoordinate with designated specialty pharmacy and follow PA/SP requirements
    inv-140: PA (restate)
    PA (restate)Prior Authorization — obtain preapproval when 'PA' is listed
    ConsequencesClaims may be denied without PA; documentation must support medical necessity
    ExamplesFound across antivirals, oncology, endocrine and specialty agents

    Initial Dispensing and Therapy Requirements

    Initial dispensing and QL — product-specific initial limits and requirements

    Initial dispensing limits and requirements are product-specific.

    Quantity limit requirement: When a product lists a QL (e.g., 30 tablets/30 days), initial and ongoing fills are limited to that quantity unless PA/override is approved.Varies by product (examples: 30 tablets/30 days, 60 capsules/30 days)

    Specific QLs vary by product and are shown on each product line (see antiviral and antiretroviral examples).

    Step Therapy Controls

    Policy elementExplanation
    Step therapy presence (ST)
    Step therapy may be required for some medications. When step therapy is commonly required, the drug list will note 'ST' under the Special Requirements column; members may need to try a specified alternative before coverage is available.
    Product examples/flagsManagement note
    Tobramycin nebulized solutions / TOBI PODHALER / inhaled aminoglycosides
    Some products are managed through specialty pharmacy (SP) and/or require prior authorization (PA) before coverage; step therapy specifics are not listed in this excerpt (see Requirements/Limits flags on product lines).
    FlagImplication
    AC (Additional Criteria)
    The 'AC' flag on selected agents indicates additional clinical criteria or administrative review may apply and that further step or authorization requirements could be enforced prior to coverage.
    Entries flaggedProgram implication
    SP (Specialty Program) on oncology/specialty agents
    Entries flagged 'SP' indicate specialty program or step requirements for certain oncology and specialty agents; specific prior steps or sequences are not listed in the provided excerpt.
    ObservationNote
    No explicit multi-step sequences in excerpt
    The document segment primarily uses PA, QL, and SP flags for control; explicit step therapy sequences (e.g., required prior drugs and failure criteria) are not specified in these chunks.
    ProductRequirements/Limits
    tamoxifen citrate 10 mg / 20 mg
    Listed with 'AC' in Requirements/Limits — follow the payer's additional criteria and authorization process for access (AC may indicate administrative/clinical review).
    Product groupRequirements/Limits
    Contraceptive oral products (examples: drospirenone-ethinyl estradiol, levonorgestrel combos, ELLA)
    Some contraceptive products show 'AC' and 'PA' with QL (e.g., 28 tablets/21 days) indicating additional administrative steps and prior authorization requirements before coverage. Specific step sequences are not provided.
    General controlImplication for coverage
    PA or QL documented
    Documented prior authorization (PA) or a specified quantity limit (QL) applies before coverage where noted; explicit step sequences are not listed in the cited chunks. Providers must submit required PA documentation when indicated.
    Products markedCoverage condition
    Products marked 'SP'
    Products designated 'SP' are subject to specialty pharmacy program requirements and may also be assigned step program controls as a condition of coverage. Specific prior steps are not detailed here.
    SummaryActionable detail
    No explicit step-therapy sequences provided
    This document segment uses tiering and utilization flags (PA, QL, SP, AC) rather than listing step-therapy algorithms; follow payer step edit rules and PA processes where 'ST' or 'SP' flags are present.
    Control approachInterpretation
    Tiering with PA/QL/SP controls
    The formulary segment applies tier assignments plus PA/QL/SP flags for utilization management; explicit multi-step therapy steps are not provided in this excerpt. Providers should obtain PA when 'PA' is indicated.
    Excerpt contentImplication
    PA/QL/SP flags present
    The cited chunks list products with PA, QL, and SP flags but do not include explicit step therapy step sequences; use the flags to determine authorization and dispensing requirements.
    Agent groupStep therapy application
    Selected antidepressants and CNS agents (examples: AUVELITY, DESVENLAFAXINE ER, FETZIMA, FLUOXETINE DR, PAROXETINE formulations, SERTRALINE)
    Certain antidepressants and related CNS agents are noted with 'ST' on the drug list, indicating step therapy applies to these products (specific step requirements not included in the excerpt).
    Products marked 'ST'Policy note
    Various listed agents across CNS and antipsychotic classes (examples: paroxetine oral suspension, clozapine ODT, select antidepressants)
    Entries marked 'ST' are subject to step therapy prior to coverage. The document does not provide the specific prior-step medication(s) or failure criteria in this excerpt; refer to the plan's step therapy protocols for details.

    Quantity Limits and Dispensing Restrictions

    inv-159: maintenance medications (general) — 30-day standard; some plans allow up to 90-day for maintenance
    Maintenance meds standard30‑day standard dispensing; some plans allow up to 90‑day supplies for maintenance medications
    Check plan benefitsPlan‑specific benefit design may permit longer fills — verify member plan materials
    Where notedDispensing limits are shown with 'QL' on product list when applied
    inv-160: azithromycin tab — 60
    Azithromycin tab QL60 tablets per 180 days
    Formulations notedAzithromycin tablets 250 mg and 500 mg listed under MACROLIDES with QL
    Provider notePrescriptions exceeding this QL may require justification or the member may incur full cost beyond coverage
    inv-161: fidaxomicin tab 200 mg — unspecified QL referenced
    Fidaxomicin QLProduct line shows a QL on fidaxomicin (DIFICID) but specific timeframe not provided in extract
    DrugDIFICID fidaxomicin 200 mg tablets (listed under MACROLIDES/anti‑infectives)
    ActionVerify the full product line on the payer drug list for the exact QL timeframe when authorizing or dispensing
    inv-162: ARIKAYCE (amikacin liposome inhal) 590 mg/8.4ml — 235.2
    ARIKAYCE QLQL (235.2 mL/28 days) for ARIKAYCE (amikacin liposome inhalation) 590 mg/8.4 mL
    SP/PAARIKAYCE listed with SP and PA designations
    Provider noteSpecialty and prior authorization processes apply for inhaled amikacin formulations
    inv-163: tobramycin nebu soln 300 mg/ml — 56
    Tobramycin neb solution QLQL (56 containers/56 days) for tobramycin nebulization solution 300 mg/mL
    SP/PATobramycin nebs are SP and may require PA per product line
    ExamplesTOBI and Bethkis entries show QL (56 containers/56 days)
    inv-164: TOBI PODHALER 28 mg inhalation capsules — 224
    TOBI PODHALER QLQL (224 capsules/56 days) for TOBI PODHALER 28 mg inhalation capsules
    SPProduct listed with SP designation
    Provider noteFollow specialty pharmacy and quantity limits when dispensing PODHALER capsules
    inv-165: selected antiretrovirals (examples) — 30
    Typical ARV QLQL (30 tablets/30 days) is common for many antiretrovirals (examples: BIKTARVY, CIMDUO, DOVATO)
    VariationSome ARV formulations or strengths may have higher QLs (e.g., 60 tablets/30 days) or solution volumes (e.g., EMTRIVA 720 mL/30 days)
    ActionConfirm the specific product line QL before authorizing multi‑month supplies
    inv-166: BIKTARVY, GENVOYA, DOVATO, etc. — varies by product
    Variation by productSelected products (BIKTARVY, GENVOYA, DOVATO, etc.) have QLs that vary by product and formulation
    Common QLMany count‑based oral ARV products show QL (30 tablets/30 days)
    Provider actionCheck product line for exact QL and any PA/SP flags prior to dispensing
    inv-167: SUNLENCA — 4 tablets/365 days or 5 tablets/365 days for therapy packs
    SUNLENCA QLQL (4 tablets/365 days) or therapy pack QL (5 tablets/365 days)
    DrugSUNLENCA (lenacapavir) — tablet and therapy pack presentations listed
    Provider noteAnnual QL indicates limited dispensing frequency — verify pack vs tablet presentation when requesting supply
    inv-168: vancomycin hcl capsules — QL (120 capsules/30 days)
    Vancomycin capsule QLQL (120 capsules/30 days) for vancomycin HCl capsules (Vancocin)
    Oral solutionVancomycin oral solutions listed but QL not shown in this excerpt
    Provider actionFollow QL for capsules to avoid exceeding covered quantity
    inv-169: XIFAXAN rifaximin 200 mg — QL (9 tablets/30 days)
    XIFAXAN 200 mg QLQL (9 tablets/30 days) for XIFAXAN 200 mg
    IndicationListed under anti‑infectives (rifaximin) with product‑specific QL
    Provider noteShort‑course QL reflects labeled uses — check diagnosis and dosing when submitting PA if needed
    inv-170: XIFAXAN rifaximin 550 mg — QL (60 tablets/30 days)
    XIFAXAN 550 mg QLQL (60 tablets/30 days) for XIFAXAN 550 mg
    Formulation noteHigher QL for 550 mg formulation reflects differing indications/packaging
    Provider actionConfirm strength/formulation when determining allowed quantity
    inv-171: various antineoplastics — examples include QL (60 tablets/30 days), QL (240 capsules/30 days), QL (120 tablets/30 days)
    Antineoplastic QL examplesExamples include QL (60 tablets/30 days), QL (240 capsules/30 days), QL (120 tablets/30 days) depending on product
    Product variabilityMany oncology agents have PA and SP flags in addition to QL — verify full product line
    Provider actionObtain PA and adhere to QL when prescribing antineoplastics to ensure coverage
    inv-172: SIVEXTRO tedizolid 200 mg — QL (6 tablets/180 days)
    SIVEXTRO QLQL (6 tablets/180 days) for SIVEXTRO (tedizolid) 200 mg
    IndicationShort‑course oxazolidinone antibiotic — QL reflects limited use
    Provider noteRequests beyond QL may require PA or documentation of clinical need
    inv-173: nitazoxanide 500 mg (Alinia) — QL (6 tablets/30 days)
    Alinia (nitazoxanide) QLQL (6 tablets/30 days) for nitazoxanide 500 mg
    Product noteListed under anti‑infectives with limited QL for short courses
    Provider actionVerify indication and dosing when requesting beyond QL
    inv-174: AUGTYRO repotrectinib cap 160 mg — 30 capsules/30 days or 60 capsules/30 days
    AUGTYRO QL30 capsules/30 days or 60 capsules/30 days (two entries showed differing QL) for AUGTYRO repotrectinib 160 mg
    Provider noteVerify the specific pack/strength entry and QL on the payer list when authorizing therapy
    SP/PAAUGTYRO entries include SP and PA designations — obtain PA and route through specialty pharmacy as required
    inv-175: BALVERSA erdafitinib tab 3 mg — 90 tablets/30 days
    BALVERSA QLQL (90 tablets/30 days) for BALVERSA (erdafitinib) 3 mg
    Alternate strengthsOther BALVERSA strengths listed with differing QLs (e.g., 60 tablets/30 days)
    Provider actionConfirm strength and QL on product line when submitting PA or dispensing
    inv-176: BOSULIF bosutinib cap 50 mg — 30 capsules/30 days
    BOSULIF 50 mg QLQL (30 capsules/30 days) for BOSULIF bosutinib 50 mg
    SP/PABosulif entries include SP/PA in many presentations
    Provider actionCheck strength-specific QL for coverage and dispensing limits
    inv-177: BOSULIF bosutinib cap 100 mg — 150 capsules/30 days
    BOSULIF 100 mg QLQL (150 capsules/30 days) for BOSULIF bosutinib 100 mg
    NoteHigher capsule QL for this strength — verify exact product line when dispensing
    Provider actionObtain PA and follow SP routing where indicated
    inv-178: BRAFTOVI encorafenib cap 75 mg — 180 capsules/30 days
    BRAFTOVI QLQL (180 capsules/30 days) for BRAFTOVI encorafenib 75 mg
    SP/PAListed with PA and SP designations in many entries
    Provider noteHigh QL counts reflect pack sizes — confirm when authorizing and dispensing
    inv-179: COMETRIQ cabozantinib kits — 1 carton/28 days
    COMETRIQ QL1 carton/28 days for COMETRIQ cabozantinib kits
    SP/PACOMETRIQ entries include PA and SP designations
    Provider actionAdhere to kit/carton QL when arranging supply and prior authorization
    inv-180: COPIKTRA — 56 capsules/28 days
    COPIKTRA QL56 capsules/28 days for COPIKTRA
    PA/SPCOPIKTRA listed with PA and SP in the product line
    Provider noteFollow PA and specialty dispensing for coverage adherence
    inv-181: DAURISMO glasdegib 25 mg — 60 tablets/30 days
    DAURISMO QL60 tablets/30 days for DAURISMO glasdegib 25 mg
    PA/SPListed with PA and SP designations for many strengths
    Provider noteConfirm strength‑specific QL when authorizing therapy
    inv-182: ERIVEDGE vismodegib 150 mg — 30 capsules/30 days
    ERIVEDGE QL30 capsules/30 days for ERIVEDGE vismodegib 150 mg
    PA/SPERIVEDGE entries include PA and SP in many listings
    Provider actionFollow PA/SP requirements and QL when dispensing ERIVEDGE
    inv-183: ERLEADA apalutamide 60 mg — 120 tablets/30 days
    ERLEADA QL120 tablets/30 days for ERLEADA apalutamide 60 mg
    Alternate packsOther ERLEADA strengths listed with differing QLs (e.g., 30 tablets/30 days)
    Provider noteVerify formulation and QL when requesting dispensation
    inv-184: ICLUSIG ponatinib — 30 tablets/30 days
    ICLUSIG QL30 tablets/30 days for ICLUSIG (ponatinib)
    PA/SPICLUSIG entries include PA and SP flags
    Provider actionObtain PA and adhere to QL when dispensing ponatinib
    inv-185: IMBRUVICA ibrutinib oral suspension — 216 mL/30 days
    IMBRUVICA oral suspension QLQL (216 mL/30 days) for IMBRUVICA ibrutinib oral suspension
    PA/SPIMBRUVICA lines include PA and SP designations for many formulations
    Provider noteConfirm suspension QL when prescribing liquid formulation
    inv-186: KOSELUGO selumetinib 10 mg — 240 capsules/30 days
    KOSELUGO QL240 capsules/30 days for KOSELUGO selumetinib 10 mg
    Alternate strengths10 mg and 25 mg strengths list differing QLs (e.g., 120 capsules/30 days for 25 mg)
    Provider actionVerify strength-specific QL and SP/PA requirements before dispensing
    inv-187: LENVIMA therapy packs — varies by pack; examples list 30–90 capsules/30 days
    LENVIMA packs QLVaries by pack; examples list 30–90 capsules/30 days depending on therapy pack
    PA/SPLENVIMA therapy packs often include PA and SP flags
    Provider noteConfirm specific therapy pack QL when arranging supply
    inv-188: LONSURF trifluridine-tipiracil — 60 or 80 tablets/28 days depending on strength
    LONSURF QLQL (60 or 80 tablets/28 days) depending on strength for LONSURF trifluridine‑tipiracil
    PA/SPLONSURF listed with PA and SP for many entries
    Provider actionConfirm strength-specific QL when authorizing LONSURF
    inv-189: MEKINIST trametinib solution — 13 bottles/28 days
    MEKINIST QLQL (13 bottles/28 days) for MEKINIST trametinib solution
    PA/SPMEKINIST entries include PA and SP flags
    Provider noteCheck formulation (solution vs tablets) for the applicable QL

    Where Drugs Are Administered or Dispensed

    Billing Rule

    Check medical benefit for provider‑administered drugs

    Medications requiring professional administration may be billed to the medical benefit and not the pharmacy benefit; check site-of-care guidance and call the number on the ID card if unclear.

    • Provider-administered drugs (e.g., certain infusions, contraceptive implants) may be covered under the medical benefit rather than pharmacy.
    Note

    No site‑of‑care restrictions specified here

    No explicit site‑of‑care restrictions are provided in this extract; when present elsewhere, follow payer site‑of‑care guidance.

    Billing Rule

    Dispense 'SP' products via specialty pharmacy

    Products with 'SP' must be dispensed via specialty pharmacy channels; use the payer‑specified specialty pharmacy for these medications.

    • Specialty-designated products are expected to be dispensed via specialty pharmacy channels.
    Billing Rule

    Manage SP products through specialty channels

    Specialty‑designated products (SP) are expected to be managed through specialty pharmacy channels and may require specialty handling or distribution through infusion/home administration pathways.

    • Certain infusions and biologics designated SP may require infusion centers, specialty pharmacy, or home administration per payer guidance.
    Billing Rule

    Use specialty pharmacy for 'SP' designated products

    Products listed with 'SP' must be dispensed via specialty pharmacy; follow payer specialty pharmacy network requirements for these medications.

    • Specialty channels apply to multiple listed biologics and specialty drugs.
    Billing Rule

    Follow AC administrative pathways for select contraceptives

    Some contraceptive/vaginal products carry 'AC' indicating administrative coverage controls; follow the administrative coverage pathways or pharmacy channels designated by the plan.

    • Examples: nonoxynol-9 products and PHEXXI show AC flags.
    Billing Rule

    Route specialty products to the payer's specialty pharmacy

    Certain specialty-designated products are managed through specialty pharmacy channels; ensure prescriptions for these items are routed to the specialty pharmacy noted by the payer.

    • Specialty channel management applies to many high-cost and biologic agents.
    Note